Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 3/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.76 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | SHBG | P04278 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | MGAM | O43451 | 1/20 | 0.66 |
| ▸ | G6PD | P11413 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510938 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL23144727 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL676328 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL144878 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL37778 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL675417 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL17776486 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL12646116 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL23699767 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL19156379 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358719-A1 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-10-31 | — | — | US | claimed |
| EP-4337234-A1 | MICROBIOME MICROORGANISM AND USES THEREOF | Biomica Ltd. (IL) | 2024-03-20 | — | — | EP | claimed |
| EP-4313061-A1 | FORMULATIONS FOR PROLONGING GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117396597-A | Microbiome microorganisms and uses thereof | 生物米卡有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117202910-A | Formulations for prolonging pregnancy and for menstruation or pregnancy complications | 斯坦福大学托管董事会 | 2023-12-08 | — | — | CN | claimed |
| WO-2022239013-A1 | MICROBIOME MICROORGANISM AND USES THEREOF | BIOMICA LTD. (IL) | 2022-11-17 | — | — | WO | claimed |
| US-20220339176-A1 | Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-27 | — | — | US | claimed |
| WO-2022211810-A1 | FORMULATIONS FOR PROLONGING GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-06 | — | — | WO | claimed |
| EP-4034129-A1 | METHODS OF TREATMENTS TO PROLONG GESTATION AND COMPLICATIONS OF MENSTRUATION OR GESTATION | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-08-03 | — | — | EP | claimed |
| CN-114728013-A | Methods of treating prolonged pregnancy and complications of menstruation or pregnancy | 斯坦福大学托管董事会 | 2022-07-08 | — | — | CN | claimed |
| WO-2026076495-A1 | METHOD OF TREATMENT OR INHIBITION | TRKB Investments Pty Ltd (AU) | 2026-04-16 | — | — | WO | disclosed |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12504405-B2 | Evaporation-based sample preparation workflow for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20180050107-A1 | NEUROSTEROID COMPOSITIONS AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-22 | — | — | US | disclosed |
| WO-2018022668-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022664-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022666-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2017194748-A1 | MEDICAMENT FOR TREATMENT AND/OR PROPHYLACTIC TREATMENT OF BREAST CANCER | HAKMED AB (SE) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339176-A1 | Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation | PGF, GNRHR, PTGDR | AKR1B10 1539/4885AKR1B1 1206/4885GPBAR1 217/4885 |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | AKR1B10 559/4885AKR1B1 771/4885GPBAR1 600/4885 |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP4A11, CYP21A2, CYP17A1 | AKR1B10 901/4885AKR1B1 1735/4885GPBAR1 704/4885 |
| US-20240358719-A1 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | PGF, GNRHR, PTGDR | AKR1B10 1173/4885AKR1B1 839/4885GPBAR1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.